Back to search

FORNY20-FORNY2020

KVAL: AlbuVax- Improved mucosal vaccine delivery

Alternative title: AlbuVax - Forbedret leveranse av vaksine over slimhinne

Awarded: NOK 0.50 mill.

Project Number:

321244

Project Period:

2020 - 2021

Funding received from:

Organisation:

Location:

Most pathogens pass into their host at a mucosal surface (for example the lungs for respiratory pathogens), and delivery of vaccines through a mucosal surface is an ideal approach to achieve local as well as systemic immune protection. Yet, vaccines are usually given with needles in the skin or muscles, which is inconvenient and often provides poor protection at the actual site of infection. Thus, there is a great need for improved vaccination technologies. Scientists at Oslo University Hospital and the University of Oslo have developed a technology (called AlbuVax) that improves the ability of a vaccine to cross mucosal surface and provide protection, both for influensa and Covid19. Further development is planned to be done through a new Norwegian company. the initial structur and planning of this new company has been pert of the qualificaiton project.

Despite general interest in the technology with different important players in the vaccine system, engagement with the identified industry during the qualification project has not resulted in licensing deals. Based on the partnering feedback we believe the main reason for this is the maturity of the results. Based on the preclinical effect of the AlbuVax technology for both influenza and Covid19, and general interest, it has therefore decided that the technology will be further developed in a new planned company for which preparatory work has started (dialogue with potential partners, company structure and planning). A needle-free (spray) improved vaccination technology with specific immune response close to mucosal surfaces, with likely long half-life is highly relevant for respiratory infectious diseases that are currently, and will in the future, challenge the global health systems health systems

Funding scheme:

FORNY20-FORNY2020